What Does Trelegy Ellipta Cost in 2026, and What Happens in 2027?

Trelegy Ellipta is a once-daily triple-therapy inhaler combining fluticasone furoate (an inhaled corticosteroid), umeclidinium (a long-acting muscarinic antagonist), and vilanterol (a long-acting beta-2 agonist). It is approved for adults with COPD and asthma, and in 2026, roughly 1.3 million Medicare beneficiaries use it. That scale made it one of the 15 drugs selected by CMS for Round 2 of IRA price negotiation, with the negotiated price taking effect January 1, 2027.

In 2026, the retail cash price sits at $698 to $930 per inhaler depending on the pharmacy. GSK's voluntary $35/month out-of-pocket cap for commercially insured patients, launched January 1, 2025, covers Trelegy along with its other inhaled COPD and asthma medicines. Medicare Part D patients do not qualify for that commercial savings card but are covered by the upcoming $175/month negotiated price starting in 2027 and by the 2026 annual $2,100 Part D out-of-pocket cap in the meantime.

Because Trelegy is self-administered at home and dispensed through retail or mail-order pharmacies, it is billed through Medicare Part D, not Part B. It has no HCPCS J-code. During a hospital inpatient stay, respiratory medications like Trelegy are typically absorbed into the DRG-bundled facility rate rather than billed as separate line items at the retail pharmacy price. Patients who encounter a separate inhaler charge on a hospital bill should verify it is not a billing error. Patients on Medicaid typically pay $1 to $4 per prescription if Trelegy appears on their state plan's formulary.

What Trelegy Ellipta Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same trelegy ellipta can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Trelegy Ellipta is almost always dispensed at retail or mail-order pharmacies and administered by the patient at home. This makes it a Part D drug, not a Part B drug, meaning hospitals do not typically bill it as a separate line item during an inpatient stay. Instead, respiratory medications are bundled into the facility's DRG-based payment for the hospitalization. Patients should be skeptical if they see an itemized charge for Trelegy on a hospital bill: this is more likely a billing error than a legitimate separate charge.

The unusually high retail list price for Trelegy ($698 to $930 per inhaler) reflects the lack of generic competition: no FDA-approved generic equivalent exists as of 2026. The brand-only market allowed GSK to price the triple-combination inhaler at a premium. Specialty pharmacy mail order sometimes offers a modest 10% to 15% reduction on 90-day supplies, bringing the effective monthly cost slightly lower for uninsured cash-paying patients.

For Medicare Part D beneficiaries, the 2026 annual out-of-pocket cap of $2,100 means a patient spending $900 per month on Trelegy would hit the cap after 2 to 3 fills and pay $0 for the rest of the year. This IRA provision, effective January 1, 2025, already provides significant relief to the roughly 1.3 million Medicare enrollees taking Trelegy. The 2027 negotiated price of $175 per month goes further, capping the cost at a flat $175 per fill for Medicare patients regardless of plan tier.

Patient Assistance Programs

GSK runs two programs that can significantly reduce or eliminate the cost of Trelegy Ellipta depending on your insurance status:

Medicare Part D

Trelegy Ellipta is covered by Medicare Part D. Approximately 97% of Part D and Medicare Advantage prescription drug plans include it on their formulary. The specific tier placement and copay vary by plan: Trelegy typically lands on Tier 4 (non-preferred brand) or Tier 5 (specialty), which carries the highest copays before the out-of-pocket cap kicks in.

In 2026, the annual out-of-pocket cap for Part D is $2,100. This means a Part D enrollee paying the full retail-range cost for Trelegy will hit the catastrophic coverage threshold after roughly 2 to 3 months of fills and pay $0 for the remaining months of the year. This cap, part of the Inflation Reduction Act, replaced the old coverage gap (donut hole) and took full effect January 1, 2025.

Starting January 1, 2027, Trelegy Ellipta will have a Medicare Maximum Fair Price of $175 per 30-day supply, negotiated under IRA Round 2. Medicare enrollees will pay no more than this amount, and plans will be required to cover it at this price. Patients who also qualify for Extra Help (Low Income Subsidy) may pay significantly less, often $0 to $11 per fill in 2026. Check eligibility at ssa.gov/medicare/part-d-extra-help.

Common Trelegy Ellipta Billing Errors

Trelegy Ellipta is a pharmacy-dispensed drug, not a hospital-administered drug. These are the billing errors that arise most often:

• Separate line-item charge for Trelegy on an inpatient hospital bill: inhaled maintenance medications taken at home are absorbed into the DRG bundle during a hospital stay and should not appear as a retail-priced separate charge
• Medicare billing for Trelegy under Part B instead of Part D: Trelegy is self-administered at home and is a Part D benefit only; Part B covers only a narrow set of inhalation drugs administered in a clinical setting (e.g., nebulized solutions)
• Applying the GSK savings card to a Medicare or Medicaid claim: the commercial savings card cannot legally reduce cost-sharing for government-insured patients; using it incorrectly can constitute a False Claims Act violation
• Quantity mismatch: billed for a 60-day supply but only 30 days dispensed, or two inhalers billed when one was dispensed
• Failure to apply the 2026 Part D annual out-of-pocket cap: once a Part D enrollee has paid $2,100 in covered drug costs in 2026, cost-sharing drops to $0; pharmacies that continue collecting copays after the cap is reached are billing incorrectly

Frequently Asked Questions